An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Neil L. Spector, Sumin Zhao et al.|Breast Cancer Research|2013Cited by 146